Join the Renal Cell Carcinoma group to help and get support from people like you.
Renal Cell Carcinoma News
Related terms: Adenocarcinoma of renal cells, Cancer, Hypernephroma, Cancer, Kidney, Cancer, Renal, Cancer, Renal Cell Carcinoma, Hypernephroma, Kidney Cancer, Renal Cancer
Firefighters Face Elevated Mortality Rates for Skin and Kidney Cancer
FRIDAY, Aug. 1, 2025 – Occupation as a firefighter is associated with elevated cancer mortality, especially for skin and kidney cancer, according to a study published online July 29 in the...
Immune Checkpoint Inhibitor Affordability Tied to Widening Survival Disparity
FRIDAY, July 11, 2025 – The introduction of immune checkpoint inhibitors (ICIs) was associated with a widening survival disparity between those with private insurance and those without health...
Urine Test Sensitive for Renal Cancer Recurrence After Surgery
WEDNESDAY, March 26, 2025 – Urine glycosaminoglycan profiles (GAGomes) have high sensitivity for nonmetastatic clear-cell renal cell carcinoma (M0ccRCC) recurrence, according to a study presented at...
Lifetime Excess Weight, Adult Weight Gain Linked to Increased Renal Cancer Risk
MONDAY, March 24, 2025 – Lifetime excess weight and adult weight gain are associated with an increased risk for renal cell carcinoma (RCC), according to a study published online March 24 in Cancer....
Immunogenic Cancer Vaccine Targets Key Mutations in Kidney Cancer
THURSDAY, Feb. 6, 2025 – Neoantigen-targeting personalized cancer vaccines (PCVs) are highly immunogenic in high-risk clear cell renal cell carcinoma (RCC) and can target key driver mutations and...
Therapeutic Vaccine May Fight Advanced Kidney Cancer
THURSDAY, Feb. 6, 2025 – A small, early trial of a vaccine that mobilizes the immune system to battle advanced kidney cancers appears successful, researchers report. The "personalized cancer...
FDA Approves Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) Subcutaneous Injection for Use in Most Previously Approved Solid Tumor Opdivo (nivolumab) Indications
PRINCETON, N.J.--(BUSINESS WIRE) December 27, 2024 – Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) granted approval for Opdivo Qvantig (nivolumab...
Arsenic in Drinking Water Tied to Kidney Cancer Risk
THURSDAY, Dec. 19, 2024 – Even low levels of arsenic exposure in drinking water may increase the risk for kidney cancer, according to a study published online Dec. 15 in Environmental Pollution....
Novel Imaging Technique Accurate for Detecting Clear-Cell Renal Cell Cancer
MONDAY, Oct. 21, 2024 – ⁸⁹Zr-labeled monoclonal antibody ([⁸⁹Zr]Zr-girentuximab) for positron emission tomography-computed tomography (PET-CT) is accurate for detecting patients with clear-cell renal...
Tivozanib Has Efficacy in Advanced Renal Cell Carcinoma Post-ICI Therapy
FRIDAY, Sept. 20, 2024 – For patients with metastatic renal cell carcinoma (mRCC) and progression during or after one to two prior lines of therapy, including one immune checkpoint inhibitor (ICI),...
Combo Treatment Doubles Survival for Patients With Advanced Kidney Cancer
TUESDAY, Sept. 17, 2024 – A small clinical trial suggests that a duo of drugs can extend survival for people battling advanced kidney cancer. Researchers at Roswell Park Comprehensive Cancer...
Belzutifan Improves Progression-Free Survival in Advanced Renal Cell Cancer
FRIDAY, Aug. 23, 2024 – Belzutifan, a hypoxia-inducible factor 2α (HIF-2α) inhibitor, improves progression-free survival and objective responses over everolimus among patients with advanced c...
FDA Approves Merck’s Welireg (belzutifan) for the Treatment of Patients With Advanced Renal Cell Carcinoma (RCC) Following a PD-1 or PD-L1 Inhibitor and a VEGF-TKI
RAHWAY, N.J.--(BUSINESS WIRE) December 14, 2023 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has...
FDA Approves Vegzelma (bevacizumab-adcd), a Biosimilar to Avastin
Vegzelma is Celltrion’s third oncology biosimilar to receive approval from the U.S. FDA Vegzelma offers U.S. patients living with multiple types of cancer a new, safe, and effective treatment option ...
FDA Approves Alymsys (bevacizumab-maly), a Biosimilar to Avastin
BRIDGEWATER, N.J.--(BUSINESS WIRE) April 13, 2022 --Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved ...